PAC-14028
Phase 2Small molecule
PAC-14028 is one of 68 small molecule programs targeting Rosacea. It is currently in Phase 2.
4
Indications
11
Total Trials
0
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Rezzayo
RochePhase 3
Immunotherapy
Bristol-Myers SquibbPhase 3
VC005
JJiangsu vcare pharmaceutical technology co., LTD
Phase 3
EBGLYSS
Eli LillyPreclinical
PAC-14028
AAmorepacific Corporation
Phase 2
Cibinqo
PfizerPreclinical
Prograf
VVeloxis Pharmaceuticals
Preclinical
Adtralza
LEO PharmaPreclinical
V0034CR01B
PPierre Fabre Medicament
Phase 3
Rituxan
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atopic Dermatitis4 trials
Rosacea2 trials
Pruritus2 trials
Seborrheic Dermatitis1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PAC-14028. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAmorepacific Corporation